NCT03805841: A trial that was reported late by Rain Oncology Inc
This trial has reported, although it was 353 days late in doing so.
Full data
| Full entry on ClinicalTrials.gov | NCT03805841 |
|---|---|
| Title | Phase 2 Study - Evaluate the Clinical Activity of Tarloxotinib in Patients With Non-Small Cell Lung Cancer That Harbors an EGFR Exon 20 Insertion or HER2-Activating Mutation and Other Advanced Solid Tumors With NRG1/ERBB Family Gene Fusions |
| Results Status | Reported (late) |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | March 13, 2019 |
| Completion date | April 9, 2021 |
| Required reporting date | April 9, 2022, midnight |
| Actual reporting date | March 28, 2023 |
| Date last checked at ClinicalTrials.gov | April 4, 2025 |
| Days late | 353 |